MedTrace Logo

Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg

NCT00919477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 712

Last updated 2013-01-23

No results posted yet for this study

Summary

To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including surgical castration).

Conditions

Sponsors & Collaborators

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00919477 on ClinicalTrials.gov